Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Accounts Payables: 2020-2024

Historic Accounts Payables for Relay Therapeutics (RLAY) over the last 5 years, with Dec 2024 value amounting to $14.1 million.

  • Relay Therapeutics' Accounts Payables fell 59.92% to $2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.8 million, marking a year-over-year decrease of 59.92%. This contributed to the annual value of $14.1 million for FY2024, which is 53.05% up from last year.
  • According to the latest figures from FY2024, Relay Therapeutics' Accounts Payables is $14.1 million, which was up 53.05% from $9.2 million recorded in FY2023.
  • Relay Therapeutics' 5-year Accounts Payables high stood at $14.1 million for FY2024, and its period low was $6.4 million during FY2020.
  • Its 3-year average for Accounts Payables is $11.3 million, with a median of $10.6 million in 2022.
  • As far as peak fluctuations go, Relay Therapeutics' Accounts Payables dropped by 12.92% in 2023, and later skyrocketed by 53.05% in 2024.
  • Relay Therapeutics' Accounts Payables (Yearly) stood at $6.4 million in 2020, then soared by 30.31% to $8.3 million in 2021, then grew by 27.82% to $10.6 million in 2022, then fell by 12.92% to $9.2 million in 2023, then surged by 53.05% to $14.1 million in 2024.